Inflammatory Bowel Disease: Percentage of patients diagnosed with extensive mild-moderate ulcerative colitis that receive a high- (>3 g/d) or standard-dose mesalamine (2-3 g/d) or diazo-bonded 5-aminosalicylate (5-ASA) rather than low dose mesalamine (<2 g/d), sulfasalazine or no treatment.

How to implement this AGA quality measure
Access AGA’s quality measures at www.gastro.org/quality